326329
Policies and Behaviors Driving Adoption of Health IT in Substance Abuse Treatment - The Evidence to Date
Our team will explore specific aspects of the substance abuse landscape and how the policy and fiscal environment has established barriers to the adoption and meaningful use of technology in behavioral health practice. To understand these barriers, we will use a case study of a substance abuse facility that is ongoing, explore research to date on the transition to use of health information technology, and highlight the overall results of adoption efforts nationwide.
Lastly, we will draw on Deloitte’s research in behavioral health issues to highlight how substance abuse facilities have developed innovative programs to implement various aspects of health IT, and their progress to date.
Learning Areas:
Public health or related public policySocial and behavioral sciences
Learning Objectives:
Describe the current landscape for use of healthcare information technology and explore Deloitte’s research to date in this area
Explore current environmental and social factors impacting the use of health information technology in substance abuse treatment
Analyze various policy approaches designed to improve usage of health information technology, and the associated positive and negative behaviors from its use
Keyword(s): Drug Abuse Treatment, Health Systems Transformation
Qualified on the content I am responsible for because: I have worked for over 13 years in healthcare, including senior positions in federal, state, and commercial healthcare programs and initiatives, and serve in a large number of senior leadership roles within the healthcare and health IT industry. As Deloitteâs premier resource in health IT, I am responsible directly and indirectly for the development and management of over $75 million in healthcare-related work for the federal, state and commercial sectors
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.